S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
NASDAQ:TECH

Bio-Techne Stock Forecast, Price & News

$456.15
-11.12 (-2.38%)
(As of 12/3/2021 04:00 PM ET)
Add
Compare
Today's Range
$449.75
$469.57
50-Day Range
$456.15
$525.06
52-Week Range
$297.90
$543.85
Volume
259,384 shs
Average Volume
250,818 shs
Market Capitalization
$17.92 billion
P/E Ratio
105.35
Dividend Yield
0.27%
Beta
1.11
30 days | 90 days | 365 days | Advanced Chart
Receive TECH News and Ratings via Email

Sign-up to receive the latest news and ratings for Bio-Techne and its competitors with MarketBeat's FREE daily newsletter.


Bio-Techne logo

About Bio-Techne

Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the following segments: Protein Sciences and Diagnostics &Genomics. The Protein Sciences segment develops and manufactures purified proteins and reagent solutions most notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies. This segment also includes protein analysis solutions that offer researchers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. The Diagnostics &Genomics segment develops and manufactures diagnostic products, including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx Prostate(IntelliScore) test (EPI) for prostate cancer diagnosis. This segment also manufactures and sells advanced tissue-based in-situ hybridization assays (ISH) for research and clinical use. The co

Headlines

Bio-Techne Is Overpriced - Here's Why - Seeking Alpha
December 3, 2021 |  seekingalpha.com
See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Life Sciences Tools & Services
Sector
Medical
Current Symbol
NASDAQ:TECH
CUSIP
87837710
Employees
2,300
Year Founded
1981

Sales & Book Value

Annual Sales
$931.03 million
Cash Flow
$7.40 per share
Book Value
$41.91 per share

Profitability

Net Income
$140.41 million
Pretax Margin
17.90%

Debt

Price-To-Earnings

Miscellaneous

Free Float
37,684,000
Market Cap
$17.92 billion
Optionable
Optionable

Company Calendar

Last Earnings
11/01/2021
Ex-Dividend
11/10/2021
Dividend Payable
11/26/2021
Today
12/05/2021
Next Earnings (Estimated)
2/01/2022
Fiscal Year End
6/30/2022

Social Links


MarketRank

Overall MarketRank

2.35 out of 5 stars

Medical Sector

245th out of 1,388 stocks

Biological Products, Except Diagnostic Industry

44th out of 202 stocks

Analyst Opinion: 1.4Community Rank: 4.3Dividend Strength: 1.7Insider Behavior: 2.5Valuation: 1.9 5 -4 -3 -2 -1 -












Bio-Techne (NASDAQ:TECH) Frequently Asked Questions

Is Bio-Techne a buy right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bio-Techne in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Bio-Techne stock.
View analyst ratings for Bio-Techne
or view top-rated stocks.

How has Bio-Techne's stock been impacted by Coronavirus (COVID-19)?

Bio-Techne's stock was trading at $180.58 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, TECH stock has increased by 152.6% and is now trading at $456.15.
View which stocks have been most impacted by COVID-19
.

Are investors shorting Bio-Techne?

Bio-Techne saw a increase in short interest in the month of October. As of October 29th, there was short interest totaling 441,500 shares, an increase of 22.7% from the October 14th total of 359,800 shares. Based on an average daily volume of 332,900 shares, the short-interest ratio is presently 1.3 days. Approximately 1.1% of the shares of the stock are short sold.
View Bio-Techne's Short Interest
.

When is Bio-Techne's next earnings date?

Bio-Techne is scheduled to release its next quarterly earnings announcement on Tuesday, February 1st 2022.
View our earnings forecast for Bio-Techne
.

How were Bio-Techne's earnings last quarter?

Bio-Techne Co. (NASDAQ:TECH) announced its quarterly earnings results on Monday, November, 1st. The biotechnology company reported $1.83 EPS for the quarter, beating the Zacks' consensus estimate of $1.72 by $0.11. The biotechnology company earned $257.72 million during the quarter, compared to analysts' expectations of $254.37 million. Bio-Techne had a trailing twelve-month return on equity of 15.86% and a net margin of 17.94%. During the same period in the prior year, the firm earned $1.15 earnings per share.
View Bio-Techne's earnings history
.

How often does Bio-Techne pay dividends? What is the dividend yield for Bio-Techne?

Bio-Techne announced a quarterly dividend on Wednesday, November 3rd. Investors of record on Friday, November 12th will be paid a dividend of $0.32 per share on Friday, November 26th. This represents a $1.28 annualized dividend and a yield of 0.28%. The ex-dividend date of this dividend is Wednesday, November 10th.
View Bio-Techne's dividend history
.

Is Bio-Techne a good dividend stock?

Bio-Techne pays an annual dividend of $1.28 per share and currently has a dividend yield of 0.27%. The dividend payout ratio of Bio-Techne is 29.56%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Bio-Techne will have a dividend payout ratio of 15.92% next year. This indicates that Bio-Techne will be able to sustain or increase its dividend.
View Bio-Techne's dividend history.

What price target have analysts set for TECH?

8 Wall Street analysts have issued 1-year target prices for Bio-Techne's shares. Their forecasts range from $400.00 to $548.00. On average, they anticipate Bio-Techne's stock price to reach $476.00 in the next year. This suggests a possible upside of 4.4% from the stock's current price.
View analysts' price targets for Bio-Techne
or view top-rated stocks among Wall Street analysts.

Who are Bio-Techne's key executives?

Bio-Techne's management team includes the following people:

What is Charles Kummeth's approval rating as Bio-Techne's CEO?

95 employees have rated Bio-Techne CEO Charles Kummeth on Glassdoor.com. Charles Kummeth has an approval rating of 73% among Bio-Techne's employees.

What other stocks do shareholders of Bio-Techne own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Techne investors own include Paychex (PAYX), Gilead Sciences (gild), NVIDIA (NVDA), AbbVie (ABBV), Amgen (AMGN), Abbott Laboratories (ABT), Cisco Systems (CSCO), Johnson & Johnson (JNJ), AT&T (T) and Boeing (BA).

What is Bio-Techne's stock symbol?

Bio-Techne trades on the NASDAQ under the ticker symbol "TECH."

Who are Bio-Techne's major shareholders?

Bio-Techne's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (11.14%), Bamco Inc. NY (3.82%), Neuberger Berman Group LLC (2.87%), Ownership Capital B.V. (2.57%), Massachusetts Financial Services Co. MA (2.05%) and Geode Capital Management LLC (1.87%). Company insiders that own Bio-Techne stock include Alpna Seth, Brenda S Furlow, Brenda S Furlow, Charles R Kummeth, Charles R Kummeth, Glenn Hedde, Harold J Wiens, James Hippel, Kim Kelderman, Norman David Eansor, Robert V Baumgartner and Roeland Nusse.
View institutional ownership trends for Bio-Techne
.

Which institutional investors are selling Bio-Techne stock?

TECH stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Invesco Ltd., Geneva Capital Management LLC, Goldman Sachs Group Inc., Ownership Capital B.V., Bank of New York Mellon Corp, New York State Common Retirement Fund, and Retirement Systems of Alabama. Company insiders that have sold Bio-Techne company stock in the last year include Brenda S Furlow, Charles R Kummeth, Glenn Hedde, James Hippel, Kim Kelderman, Norman David Eansor, and Roeland Nusse.
View insider buying and selling activity for Bio-Techne
or view top insider-selling stocks.

Which institutional investors are buying Bio-Techne stock?

TECH stock was acquired by a variety of institutional investors in the last quarter, including Geode Capital Management LLC, Marshall Wace LLP, Voya Investment Management LLC, Millennium Management LLC, Franklin Resources Inc., KBC Group NV, Van ECK Associates Corp, and Panagora Asset Management Inc..
View insider buying and selling activity for Bio-Techne
or or view top insider-buying stocks.

How do I buy shares of Bio-Techne?

Shares of TECH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bio-Techne's stock price today?

One share of TECH stock can currently be purchased for approximately $456.15.

How much money does Bio-Techne make?

Bio-Techne has a market capitalization of $17.92 billion and generates $931.03 million in revenue each year. The biotechnology company earns $140.41 million in net income (profit) each year or $4.33 on an earnings per share basis.

How many employees does Bio-Techne have?

Bio-Techne employs 2,300 workers across the globe.

Does Bio-Techne have any subsidiaries?

The following companies are subsidiares of Bio-Techne: Advanced Cell Diagnostics, Advanced Cell Diagnostics Inc., B-MoGen Biotechnologies Inc., Bio-Techne China Co. Ltd, Bio-Techne Ltd., Bionostics Inc., Cliniqa, CyVek, Exosome Diagnostics, Exosome Diagnostics Inc., MoGen Biotechnologies, Novus Biologicals, Novus Biologicals LLC, ProteinSimple, ProteinSimple Ltd., QT Holdings Corporation, Quad Technologies, Research and Diagnostic Systems Inc., Shanghai PrimeGene Bio-Tech Co. Ltd., Space Import-Export Srl, Tocris Cookson Limited, and Zephyrus Biosciences.

When was Bio-Techne founded?

Bio-Techne was founded in 1981.

What is Bio-Techne's official website?

The official website for Bio-Techne is www.bio-techne.com.

Where are Bio-Techne's headquarters?

Bio-Techne is headquartered at 614 MCKINLEY PLACE NE, MINNEAPOLIS MN, 55413.

How can I contact Bio-Techne?

Bio-Techne's mailing address is 614 MCKINLEY PLACE NE, MINNEAPOLIS MN, 55413. The biotechnology company can be reached via phone at (612) 379-8854, via email at [email protected], or via fax at 612-656-4400.


This page was last updated on 12/5/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.